Hard to Treat Diseases (HTDS)

[Bigtrade PT]

Hard to Treat Diseases Inc. is engaged in the export of biological products. The company conducts registrations, carries out clinical trials, and promotes and markets products around the world. It offers vaccines, such as Hepatitis A, Hepatitis B, varicella, poliomyelitis, influenza virus, DTaP combined, meningococcal, rabies, and inactivated Hepatitis A vaccines. The company also provides bio-pharmaceuticals, which include refined tetanus antitoxin, cerebroprotein hydrolysate, urinary kallidinogenase, ulinastatin for injection, HES 130/0.4, lumbrokinase, mycobacterium vaccae for injection, human brain natriuretic peptide, and reteplase (rPA) for injection. In addition, it engages in the registration and sale of MMR vaccines. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=HTDS